Hints and tips:
...Earlier at the conference, Amgen chief executive Robert Bradway expressed confidence his company would succeed in closing its acquisition of Horizon despite the FTC’s opposition....
...In March Pfizer swooped on Seagen, announcing a deal for a total enterprise value of $43bn, which was the largest pharmaceutical transaction announced since AbbVie agreed to buy Allergan in 2019....
...Robert Califf, head of the FDA, said the regulator strongly encouraged anyone eligible “to consider receiving a booster dose with a bivalent Covid-19 vaccine to provide better protection against currently...
...Tishman Speyer, one of New York’s largest commercial property developers, had previously secured pharmaceuticals company Pfizer as its anchor tenant for the Spiral....
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...Follow Robert on Twitter @robertshrimsley and email him at robert.shrimsley@ft.com Follow @FTMag on Twitter to find out about our latest stories first...
...Dr Robert Challen of the University of Exeter, whose modelling of the variant from India was presented to the government’s scientific advisory group, Sage, said it was hard to reach a definitive conclusion...
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...We have a blow-by-blow explanation of how this “short squeeze” has developed and Robert Armstrong has answers to the key questions, such as whether this will end badly. “Definitely,” he says....
...Robert Frenck, principal investigator for trials on under-12s of the BioNTech/ Pfizer jab at the Cincinnati Children’s Hospital Medical Center, said he expected children over the age of 12 to be vaccinated...
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...It was their company, BioNTech, that produced the Pfizer vaccine....
...The global equity strategy team at Citi, led by Robert Buckland, say stocks around the world may well be stuck over the next 12 months....
...But sales of the Ariens Ikon XD, featuring 20-inch tyres, a V-twin Kawasaki engine and ergonomic plush seat, have surged in the US during the pandemic....
...So the biggest groups — including Roberts and Kravis’ KKR, which reported bumper results on Tuesday — are moving into insurance....
...“I would say that, as a team, we've pretty well discounted a uniform V-shaped recovery. The question is, is it U-shaped, is it W-shaped or parts of it L-shaped?”...
...Deutsche Bank’s satellite-powered shipping tracker indicates that Chinese economic activity has now stopped contracting, and some economists are predicting a V-shaped recovery....
...US finance editor Robert Armstrong considers which trends are telling the real story in this video....
...Since then companies including Sanofi, GSK and Pfizer have begun to compete — though none of them have yet tested their potential vaccines in humans....
...We did this two years ago when Ian Read, the Scottish-born accountant turned businessman, announced his plans to step down as chief executive of pharmaceuticals group Pfizer....
...If the deal goes through, Michael Goettler, who runs Upjohn, Pfizer’s off-patent drugs business based in Shanghai, will become chief executive of the new venture, while Robert Coury, Mylan’s chairman, would...
...Michael Goettler, Upjohn’s president, will be chief executive of the new company while Robert Coury, Mylan’s chairman, will be executive chairman....
...Xerox wants to give HP’s board its walking papers We’re all guilty of overusing the David v Goliath trope but in the case of Xerox and HP, it really does apply....
...Robert Bradway, Amgen chairman and chief executive, said the company was able to take advantage of an opportunity presented by industry consolidation....
International Edition